Funda Meric-Bernstam MD
Surgical Oncology (Other than Breast)
Chair, Department of Investigational Cancer Therapeutics Medical Director, Institute for Personalized Cancer Therapy Nellie B. Connally Chair in Breast Cancer Research Professor, Division of Cancer Medicine and Surgery
Join to View Full Profile
1515 Holcombe BlvdHouston, TX 77030
Phone+1 713-792-6161
Fax+1 713-745-7296
Dr. Meric-Bernstam is on Doximity
As a Doximity member you'll join over two million verified healthcare professionals in a private, secure network.
- Gain access to free telehealth tools, such as our “call shielding” and one-way patient texting.
- Connect with colleagues in the same hospital or clinic.
- Read the latest clinical news, personalized to your specialty.
Education & Training
University of MichiganResidency, Surgery, 1991 - 1998
Yale School of MedicineClass of 1991
Certifications & Licensure
FL State Medical License 2021 - Present
OK State Medical License 2020 - 2027
AL State Medical License 2023 - 2026
AZ State Medical License 2023 - 2026
GA State Medical License 2023 - 2026
LA State Medical License 2023 - 2026
MS State Medical License 2023 - 2026
American Board of Preventive Medicine Clinical Informatics
American Board of Surgery Surgery- Join now to see all
Awards, Honors, & Recognition
- CMS Meaningful Use Stage 1 Certification ClinicStation, UT MD Anderson Cancer Center, 2013, 2015
- America's Top Doctors Castle Connolly, 2012-2014
- Top Doctors:SE Texas Castle Connolly, 2013
Clinical Trials
- Bevacizumab in Multiple Phase I Combinations Start of enrollment: 2007 Oct 10
- Axillary Reverse Mapping for Invasive Carcinoma of the Breast Start of enrollment: 2008 Mar 01
- Ixabepilone in Treating Participants With Significant Residual Disease of HER2/Neu Negative Invasive Breast Cancer After Systemic Therapy Start of enrollment: 2009 Mar 30
Publications & Presentations
PubMed
- Outcomes of patients with or without DNA repair pathway alterations: the MD Anderson IMPACT2 study.Jacopo Venturini, Mehmet A Baysal, Abhijit Chakraborty, Timothy A Yap, Siqing Fu
NPJ Precision Oncology. 2026-04-10 - Post-Hoc Analysis of the Phase II DESTINY-PanTumor02 Study: Local and Central HER2 IHC Concordance and Trastuzumab Deruxtecan Efficacy by HER2 IHC Status in HER2-Expre...Vicky Makker, Jung-Yun Lee, Do-Youn Oh, Ana Oaknin, Soham Puvvada
Clinical Cancer Research. 2026-04-09 - Implications for Sentinel Lymph Node Biopsy Omission in Patients with Early-Stage Node-Negative HR+/HER2- Breast Cancer Undergoing Mastectomy.Jennifer H Chen, Kerollos Nashat Wanis, Mahdia Rahman, Ayushi Gianchandani, Isabelle Bedrosian
Annals of Surgical Oncology. 2026-04-08
Lectures
- Phase Ib study of MIW815 (ADU-S100) in combination with spartalizumab (PDR001) in patients (pts) with advanced/metastatic solid tumors or lymphomas.2019 ASCO Annual Meeting - 6/1/2019
- Preliminary Results of the Stapled Peptide ALRN-6924, a Dual Inhibitor of MDMX and MDM2, in Two Phase IIa Dose Expansion Cohorts in Relapsed/Refractory TP53 Wild-Type ...2018 ASH Annual Meeting - San Diego, CA - 12/1/2018
- Single agent activity of ZW25, a HER's targeted bispecific antibody, in heavily pretreated HERs' expressing cancers.2018 ASCO Annual Meeting - Chicago, Illinois - 06/1/2018
Press Mentions
MD Anderson Unveils Breakthrough Research Findings – February 10, 2025February 10th, 2025- MD Anderson Research Highlights for May 8, 2024May 8th, 2024
- Datopotamab Deruxtecan Showed Encouraging and Durable Efficacy in Patients with Heavily Pretreated HR Positive, HER2 Low or Negative Metastatic Breast CancerDecember 8th, 2022
Grant Support
- Center for Clinical and Translational SciencesUNIVERSITY OF TEXAS HLTH SCI CTR HOUSTON2024–2031
- Training of Academic Surgical OncologistsUNIVERSITY OF TX MD ANDERSON CAN CTR1994–2028
- A phase II multi-center trial evaluating dual targeting of the PI3K/AKT and NOS pathways for treating metaplastic breast cancer (MpBC)METHODIST HOSPITAL RESEARCH INSTITUTE2022–2027
- Discovery of the next-generation RET-targeted drugs based on nicotinamide scaffoldUNIVERSITY OF OKLAHOMA HLTH SCIENCES CTR2022–2027
- Texas EXperimental Cancer Therapeutics Network - TEX CTNUNIVERSITY OF TX MD ANDERSON CAN CTR2014–2026
Professional Memberships
- Member
- Member
Viewing the full profile is available to verified healthcare professionals only.
Find your profile and take control of your online presence:
